About this Research Topic
The present Frontiers Research Topic will focus on the results, techniques and methods used in nuclear imaging and the combination of different modalities of imaging and computing science, for diagnosis of neurodegerative diseases, which includes development of radiopharmaceuticals, diagnosis of neurodegeneration particularly using PET or SPECT, establishment of new imaging analytical methods and so on.
Development of radiopharmaceuticals is a major step for nuclear imaging, specific probes which cross blood brain barrier with appropriate pharmacological properties will be beneficial for diagnosis of neurodegenerative diseases. And preclinical evaluation of these novel molecular probes in animal models is important for clinical translational.
The second field is clinical application for diagnosis of neurodegeneration using nuclear imaging tools. Many radiotracers were present in clinic, such as 18F-FDG for glucose metabolism, 11C-CFT for dopamine transporter, 18F-AV45 targeted Aβ, 11C-PBB3 targeted tau peptide and 18F-DTBZ for mapping VMAT-2. Clinical imaging analysis of these tracers and many other tracers in patients is significant in clinic, results from this field will help other physicians to better understand the link among imaging, brain disease and their mechanism. And the new analytical methods will improve the clinical efficiency and provide better imaging quality, more and more scientists pay attention in establishment of new methods in nuclear imaging. Computing science plays a key role in imaging now.
Therefore, this Research Topic welcomes experts from various related fields to submit their work which will attract a broader readership. Submission will include the above fields, but is not limited to that. This Research Topic will cover the recent advances in imaging of neurodegeneration.
Keywords: PET imaging, neurodegenerative diseases, radiopharmaceuticals, multi-modalities, computing science
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.